GHO Capital acquires Scientist.com, the leading AI-powered R&D orchestration platform
Transaction underscores GHO’s strategy of backing category leaders across preclinical and clinical R&D services
- Scientist.com is the market-leading digital platform for outsourced R&D, trusted by the world’s top biopharma companies and thousands of pre-vetted suppliers of scientific services and products.
- GHO’s deep sector knowledge and proven record of scaling life sciences businesses will accelerate Scientist.com’s next phase of global growth.
London, UK — 16 September 2025: GHO Capital Partners LLP (“GHO”), the specialist investor in global healthcare, today announces it has entered into a definitive agreement to acquire Scientist.com, the AI-powered R&D orchestration platform that enables pharmaceutical and biotech companies to source and manage outsourced research from a global network of pre-approved suppliers.
The acquisition expands GHO’s portfolio of category-leading companies delivering innovative solutions that improve efficiency, compliance, and impact across healthcare and life sciences. Scientist.com’s sector focus on pharmaceutical R&D services, biotechnology, life science tools, and contract research aligns directly with GHO’s areas of deep expertise. Together, the partnership creates powerful synergies to fuel Scientist.com’s expansion through global reach, strategic partnerships, and selective acquisitions.
